摘要
Abstract
Objective To explore the clinical effect of Azithromycin for Injection in the treatment of pediatric Mycoplasma pneumonia.Methods A total of 92 children with Mycoplasma pneumonia admitted to the Department of Pharmacy,Jinan Children's Hospital from September 2022 to September 2023 were selected as the study subjects.All the children were divided into the reference group and the treatment group according to the odd and even number method,with 46 cases in each group.The reference group was given routine treatment,while the treatment group was treated with Azithromycin for Injection on the basis of the reference group.The levels of inflammatory factors,symptom recovery time,and clinical efficacy were compared between the two groups.Results After treatment,the tumor necrosis factor-α,interleukin-6,and hypersensitive C-reactive protein in both groups were lower than those before treatment,and the levels in the treatment group were lower than those in the reference group,and the differences were statistically significant(P<0.05).The recovery time of cough,fever,chest X-ray,and lung rales in the treatment group was shorter than that in the reference group,and the difference was statistically significant(P<0.05).The total clinical effective rate in the treatment group was 97.83%,which was higher than 82.61% in the reference group,and the difference was statistically significant(P<0.05).Conclusion The clinical effect of Azithromycin for Injection in the treatment of pediatric Mycoplasma pneumonia is good,and can shorten the recovery time of symptoms,reduce inflammation reactions,and is more suitable for pediatric Mycoplasma pneumonia.关键词
注射用阿奇霉素/小儿支原体肺炎/炎症因子Key words
Azithromycin for Injection/Pediatric Mycoplasma pneumonia/Inflammatory factor分类
医药卫生
